1. RNA sequencing-based identification of potential targets in acute myeloid leukemia: A case report
- Author
-
Ahlam Alqatari, Omar S. El‑Masry, Ali M. Al‑Amri, and Khaldoon Alsamman
- Subjects
0301 basic medicine ,succinate receptor 1 ,Biology ,acute myeloid leukemia ,ADGRA3 ,Bioinformatics ,General Biochemistry, Genetics and Molecular Biology ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,Gene expression ,medicine ,Succinate receptor 1 ,General Pharmacology, Toxicology and Pharmaceutics ,Gene ,Oncogene ,General Neuroscience ,RNA ,Myeloid leukemia ,Cancer ,RNA sequencing ,General Medicine ,Articles ,medicine.disease ,transmembrane-4 L-six family member-1 ,030104 developmental biology ,Rh associated glycoprotein ,030220 oncology & carcinogenesis - Abstract
Acute myeloid leukemia (AML) refers to heterogenous types of blood cancer which possess a complicated genomic landscape, and multiple novel mutational alterations are frequently being reported. Herein, a case report of a 37-year old AML patient is presented, who was diagnosed following laboratory investigation after admission. The patient had thrombocytopenia, and three consecutive blast counts of 40, 30 and 41%, respectively. A blood sample was collected for whole-genome RNA sequencing to understand the transcriptomic profile at the time of diagnosis and compared with a matched female control. Gene expression was quantified using the RSEM software package. Bioinformatics analysis revealed a significant number of differentially expressed genes in the patient, suggesting a marked change in the transcriptomic landscape in this patient. By mining the bioinformatics data and screening the highly expressed genes with ≥80% probability of gene expression, four novel genes were highlighted that may serve as potential future targets in AML patients; Rh associated glycoprotein, succinate receptor 1, transmembrane-4 L-six family member-1 and ADGRA3, although further validation of their value is required.
- Published
- 2020